CGEN — Compugen Ltd.

Compugen Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Cash Position: As of June 30, 2026, Compugen reported approximately $125.3 million in cash, cash equivalents, and marketable securities, providing a runway into 2029.
• Revenue: Q2 2026 revenues were $2.6 million, an increase from $1.3 million in Q2 2025, primarily due to milestone payments from Gilead.
• Expenses: R&D expenses rose to $6.3 million from $5.6 million year-over-year, while G&A expenses remained stable at $2.3 million.
• Net Loss: The net loss for Q2 2026 was approximately $7 million or $0.07 per share, slightly improved from a loss of $7.3 million or $0.08 per share in Q2 2025.

2. Strategic Updates and Business Highlights

• MAIA-Ovarian Trial: Progressing as planned, with an interim analysis expected by Q1 2027. The trial evaluates COM701 for platinum-sensitive ovarian cancer, with a focus on achieving a median progression-free survival (PFS) of at least 6 months.
• Rilvegostomig Development: AstraZeneca has initiated a new Phase III trial for rilvegostomig in urothelial carcinoma, adding to its robust pipeline of 12 Phase III studies. Recent data presented at ASCO showed promising overall survival results in advanced biliary tract cancer.
• GS-0321 Progress: The Phase I trial for GS-0321 continues to advance, with potential milestone payments from Gilead totaling up to $758 million.

3. Forward Guidance and Outlook

• Compugen maintains its guidance for the MAIA-ovarian trial results to be reported by Q1 2027. The company is optimistic about the potential of COM701 based on emerging clinical data and is focused on maintaining its cash runway to support ongoing trials and early-stage pipeline investments.

4. Bad News, Challenges, or Points of Concern

• Revised Control Arm Assumption: The estimated median PFS for the placebo control group in the MAIA trial has been adjusted to approximately 4 months, down from previous expectations, due to data from external trials indicating shorter PFS durations.
• Regulatory Engagement: Compugen has not yet engaged with the FDA regarding potential expedited approval pathways for the MAIA trial, which may pose a risk if robust data is not achieved.
• Market Competition: The competitive landscape in oncology remains intense, with multiple players advancing similar therapies, which could impact the commercial potential of Compugen’s products.

5. Notable Q&A Insights

• Patient Population Concerns: During Q&A, it was clarified that the MAIA trial's patient population is less heavily pretreated compared to recent trials cited, which may influence the trial's outcomes.
• Biomarker Strategy: Compugen does not currently have a specific biomarker strategy for the MAIA trial but will analyze exploratory data post-study.
• AstraZeneca Collaboration: The new Phase III trial for rilvegostomig does not alter existing milestone agreements, and formal data from these studies is expected post-2027, with potential interim analyses earlier.

Overall, Compugen reported steady progress in its clinical programs while navigating challenges related to evolving trial assumptions and competitive pressures in the oncology space.